Related Experiment Video

Updated: Jul 14, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Aberrant kinase signaling: lessons from head and neck cancer

Elizabeth G Nelson1, Jennifer R Grandis

  • 1Department of Otolaryngology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

Future Oncology (London, England)
|June 6, 2007
PubMed

Insights

Targeting aberrant kinase signaling in head and neck squamous cell carcinoma (HNSCC) with small molecules and monoclonal antibodies shows promise for new cancer treatments. These targeted therapies are advancing to clinical use, enabling personalized treatment strategies for HNSCC patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Cancers, including head and neck squamous cell carcinoma (HNSCC), exhibit elevated expression of receptor and nonreceptor tyrosine kinases.
  • Aberrant kinase signaling is a hallmark of HNSCC, driving tumor growth and progression.

Purpose of the Study:

  • To review the development and therapeutic potential of kinase inhibitors for HNSCC treatment.
  • To highlight the role of targeted therapies in managing HNSCC.

Main Methods:

  • Review of preclinical and clinical studies on small molecule kinase inhibitors.
  • Analysis of monoclonal antibody-based therapies targeting receptor tyrosine kinases.
  • Examination of emerging serine/threonine kinase inhibitors.

Main Results:

  • Small molecule kinase inhibitors demonstrate significant antitumor effects in preclinical models.
  • Cetuximab, an EGFR-targeting antibody, is approved for HNSCC, representing a significant therapeutic advance.
  • Development of serine/threonine kinase inhibitors is underway for clinical application.

Conclusions:

  • Targeted inhibition of aberrant kinase signaling offers a rational approach to HNSCC treatment.
  • Emerging kinase-targeted therapies hold promise for improving patient outcomes in HNSCC.
  • Personalized treatment regimens based on tumor kinase profiles are becoming feasible for HNSCC.

More Related Videos

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

Isolation and Characterization of a Head and Neck Squamous Cell Carcinoma Subpopulation Having Stem Cell Characteristics11:28

Isolation and Characterization of a Head and Neck Squamous Cell Carcinoma Subpopulation Having Stem Cell Characteristics

Published on: May 11, 2016

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...